Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Lilly offers optimistic predictions for medium-term trajectory

Lilly offers optimistic predictions for medium-term trajectory

8th January 2015

Lilly has announced its 2015 financial guidance, outlining its optimistic plans to grow revenue and expand margins over the second half of the decade.

The company's revenue for the year is anticipated to be between $20.3 billion and $20.8 billion (13.49 billion pounds and 13.88 billion pounds), with earnings per share of between $2.40 to $2.50 on a reported basis.

Year-on-year revenue growth and expanding margins are expected in the medium term, with a first wave of new product launches in diabetes, oncology and immunology to be followed by a second wave of cardiovascular disease, Alzheimer's disease, pain and oncology therapies.

The Novartis Animal Health and Lohmann Animal Health acquisitions will also be strategically crucial, helping the company recover from a recent challenging period of patent expirations.

Dr John Lechleiter, Lilly's chairman, president and chief executive officer, said: "Our refined strategic direction gives us a blueprint that will provide greater focus for our research and commercial activities and help Lilly respond to an ever more challenging environment."

Earlier this week, the company named Darren Carroll as its new senior vice-president of corporate business development, taking responsibility for the firm's future strategic corporate transactions.ADNFCR-8000103-ID-801769211-ADNFCR

We currently have 10 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.